Page 94 - Haematologica Vol. 110 - January 2025
P. 94
ARTICLE - LP-118: a promising treatment for CLL J. Ravikrishnan et al. A
B
C
Figure 4. LP-118 targets RS4;11 cells with BCL2 G101V mutation and cells lines without strong BCL2 dependency. (A) RS4;11 cells with wild-type (WT) BCL2 or overexpressing (OE) G101V BCL2 (G101VOE) were treated with increasing concentrations of venetoclax or LP-118. (Left) Cells were treated for 4 hours (hr) and stained with BAK antibody used to determine active BAK conformation and analyzed on a flow cytometer. Plots display mean ± Standard Deviations (SD), N=3 independent experiments. *P≤0.05,
Haematologica | 110 January 2025
86
Continued on following page.
